- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03199677
A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer
An Exploratory Single-center, Open-label , Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer
Studie Overzicht
Gedetailleerde beschrijving
This is a single-center, open-label, single arm,exploratory clinical trial evaluating the efficacy and safety of Apatinib in patients with local progressive/metastatic refractory thyroid cancer.
The primary endpoint is objective response rate(ORR),the secondary endpoints include progression-free-survival(PFS);disease control rate(DCR);serum Tg、TgAb、calcitonin;safety.
If any case happens as following,including withdrawing informed consent form(ICF)、unbearable toxicity or adverse reactions、other conditions which investigators think the patients are unsuitable to go on trail,the patient will not go on trial any longer,or every subject will obtain study treatment until tumor progress with CT/MRI proof.The indicators of efficacy and safety will be always observed during the trail process.
Studietype
Inschrijving (Verwacht)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Werving
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Dawei Wu, professor
- Telefoonnummer: 13521689314
- E-mail: cancergcp@163.com
-
Hoofdonderzoeker:
- Shengyu Zhou, professor
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- ≥18 years old,gender limitation.
- The pathologic subtype of thyroid carcinoma, which was confirmed by histopathological histology, included iodine refractory thyroid papillary carcinoma and follicular carcinoma, medullary thyroid carcinoma and undifferentiated carcinoma.
- Patients with at least one measurable lesion (RECIST1.1), at least one measurable lesion after the treatment (spiral CT scan length to diameter 10 mm or higher, according with the requirement of RESCIST version 1.1 standard).
Radioactive iodine deficiency (according with one of the following conditions):
- The target lesion was completely deprived of iodine in the treatment of radioactive iodine;
- The patients were treated with single dose of iodine (3.7 GBq) and the disease progressed in 12 months;
- The patients were given an iodine treatment interval of less than 12 months, and the dose was greater than that 3.7 GBq [≥100mCi], with at least one iodine treatment over 12 months of disease progression;
- Cumulative doses of radioactive iodine were greater than 22.2 GBq (or more than 600 mCi).
- Patients who underwent at least one failure of standard chemotherapy can be recommended to get into the group.
Organs function have to be compliant with the following specifications:
ANC≥1.5×109/L; PLT≥100×109/L; Hb≥90g/L; TBIL≤1.5×ULN; ALT &AST ≤2.5×ULN ; ALT &AST ≤5×ULN in patients with hepatic metastasis; BUN & Cr≤1×ULN, CCR≥50mL/min (Cockcroft-Gault formula); Normal coagulation function (INR<1.5 or PT<ULN+4s or APTT<1.5 ULN); Urinary protein<++ or urine protein quantitation in 24 hours ≤1.0 g.
- Life expectancy ≥ 12 weeks.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0~2.
- Pre-menopausal women must have a negative pregnancy test within 7 days before study entry and agree to use a medically acceptable method of contraception throughout the treatment periods and for at least six weeks after treatment discontinuation.
- The subjects volunteered to participate in the study, sign informed consent forms, and compliance with follow-up.
Exclusion Criteria:
- The presence of a third interstitial fluid (such as a large amount of pleural effusion and/or peritoneal fluid, pericardial fluid) that cannot be controlled by a drainage or other methods.
- Before or at the same time with other malignant tumors, except cured skin basal cell carcinoma, cervical carcinoma in situ or other effective treatment of tumors and did not see signs of disease for five years.
- The patients who used VEGFR-TKI drugs, such as Vandetanib, Cabozantinib, Lenvatinib,Sunitinib,Sorafenib in one month.
- Inability to swallow, chronic diarrhea and obstruction of the intestine, various factors which affect drug use and absorption.
- major surgical or severe trauma injuries, fractures, or ulcers before 4 weeks of enrolling , 3 weeks of radiation therapy (except for partial palliative radiation), chemotherapy, and molecular target therapy in three weeks, Treatment with nitrocarbamide or mitomycin before six weeks of enrolling.
- uncontrolled hypertension (systolic blood pressure of 140mmHg or diastolic pressure is greater than 90mmHg, despite the best drug treatment).
- Patients used to suffer from severe cardiovascular diseases: Ⅱ magnitude of myocardial ischemia and myocardial infarction, poor control of cardiac arrhythmias (including QTc interphase male ≥450ms, female≥470ms); According to NYHA standard, Ⅲ ~ Ⅳ cardiac insufficiency, or heart color indicate left ventricular ejection fraction (LVEF) < 50%.
- History of significant hemoptysis within 2 months prior to enrollment or daily hemoptysis is up to 2.5ml;with the trend of haemorrhage or prior treatment with an angiogenesis therapy.
- Significant clinical significance of bleeding symptoms or a definite bleeding tendency happened in three months prior to screening, such as gastrointestinal bleeding, bleeding ulcers, baseline period + + and above of defecate occult blood, or those with vasculitis, etc.
- Active brain metastasis, cancer meningitis, Spinal cord oppressor activity of brain metastases of, cancer, spinal cord compression patients, CT or MRI examination revealed brain or soft meningeal disease (patients who completed treatment and get stable symptoms with brain metastases can be into the group in 21 days prior to screening, without symptoms of cerebral hemorrhage).
- Imaging (CT or MRI) showed that tumor lesions were less than 5mm from the large blood vessels, or the central type of tumor that had penetrated the large blood vessels, or there is a clear pulmonary void or necrotic tumor.
- Patients accept other anti-tumor therapies at the same time.
- Treatment of thyroid cancer radiation was received 28 days prior to screening.
- Participated in other clinical trials within 4 weeks.
- Active or chronic hepatitis c and/or hepatitis b infection and other active infections (determined by the investigators).
- History of immunodeficiency disease, including human immunodeficiency virus infect(HIV), or acquired immunodeficiency disease (AID) and Congenital immunodeficiency disease, or history of organs for transplantation.
- Abdominal fistula, digestive tract perforation or intra-abdominal abscess happened within six months prior to screening.
- Within 12 months before the first treatment occurs artery / venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack (TIA), hematencephalon, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc. Received a powerful CYP3A4 inhibitor treatment in the first 7 days before the group, or received a powerful CYP3A4 inducer in the first 12 days before the study.
- According to the investigator's judgment, there is serious illness to endanger the safety of patients, the completion of the study (e.g: severe diabetes, renal insufficiency).
- A history of specific neurological or psychiatric disorders, including epilepsy or dementia.
- Other cases that the investigator found ineligible.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: apatinib with 500mg qd po
Patients administrate apatinib with the dose of 500mg once per day,half an hour after a meal.
|
Apatinib is an oral tyrosine kinase inhibitor.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
objective response rate
Tijdsspanne: 1 year
|
ORR is defined as the percentage of subjects having achieved confirmed Complete Response+Partial Response as best overall response according to Response Evaluation Criteria Solid Tumors(RECIST 1.1).
|
1 year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
progression-free-survival(PFS)
Tijdsspanne: 1 year
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.
|
1 year
|
disease control rate(DCR)
Tijdsspanne: 1 year
|
Investigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1(RECIST1.1).
|
1 year
|
serum Tg、TgAb、calcitonin
Tijdsspanne: 1 year
|
Evaluating the change of serum level of Tg,TgAb or calcitonin,assessed up to 12 months.
|
1 year
|
Adverse Events(AEs)
Tijdsspanne: 1 year
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.
|
1 year
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- AHEAD-RTC001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Vuurvaste kanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)WervingAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
Klinische onderzoeken op Apatinib
-
Peking University Cancer Hospital & InstituteWerving
-
Lei LiVoltooidChemotherapie | Recidiverend cervicaal carcinoom | Apatinib | Gerichte therapie | Aanhoudend gevorderd cervicaal carcinoom | Vasculaire endotheliale groeifactor 2-remmerChina
-
The First Affiliated Hospital of Zhengzhou UniversityWervingSlokdarmkanker door AJCC V8 StageChina
-
Peking UniversityJiangsu HengRui Medicine Co., Ltd.Werving
-
The First Affiliated Hospital of Zhengzhou UniversityWerving
-
Huazhong University of Science and TechnologyOnbekend
-
Beijing HospitalChinese Society of Clinical OncologyWerving
-
Shanghai Chest HospitalOnbekendHerhaling | Metastase | Slokdarm plaveiselcelcarcinoom | ApatinibChina
-
Peking Union Medical College HospitalVoltooid
-
Peking Union Medical College HospitalJiangsu HengRui Medicine Co., Ltd.WervingGestationele trofoblastische neoplasieChina